294 related articles for article (PubMed ID: 23772024)
1. An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H.
Hebecker M; Alba-Domínguez M; Roumenina LT; Reuter S; Hyvärinen S; Dragon-Durey MA; Jokiranta TS; Sánchez-Corral P; Józsi M
J Immunol; 2013 Jul; 191(2):912-21. PubMed ID: 23772024
[TBL] [Abstract][Full Text] [Related]
2. Atypical hemolytic uremic syndrome-associated variants and autoantibodies impair binding of factor h and factor h-related protein 1 to pentraxin 3.
Kopp A; Strobel S; Tortajada A; Rodríguez de Córdoba S; Sánchez-Corral P; Prohászka Z; López-Trascasa M; Józsi M
J Immunol; 2012 Aug; 189(4):1858-67. PubMed ID: 22786770
[TBL] [Abstract][Full Text] [Related]
3. Staphylococcal Ecb protein and host complement regulator factor H enhance functions of each other in bacterial immune evasion.
Amdahl H; Jongerius I; Meri T; Pasanen T; Hyvärinen S; Haapasalo K; van Strijp JA; Rooijakkers SH; Jokiranta TS
J Immunol; 2013 Aug; 191(4):1775-84. PubMed ID: 23863906
[TBL] [Abstract][Full Text] [Related]
4. Comparison of surface recognition and C3b binding properties of mouse and human complement factor H.
Cheng ZZ; Hellwage J; Seeberger H; Zipfel PF; Meri S; Jokiranta TS
Mol Immunol; 2006 Mar; 43(7):972-9. PubMed ID: 16023208
[TBL] [Abstract][Full Text] [Related]
5. Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site.
Jokiranta TS; Cheng ZZ; Seeberger H; Jòzsi M; Heinen S; Noris M; Remuzzi G; Ormsby R; Gordon DL; Meri S; Hellwage J; Zipfel PF
Am J Pathol; 2005 Oct; 167(4):1173-81. PubMed ID: 16192651
[TBL] [Abstract][Full Text] [Related]
6. FHR-1 Binds to C-Reactive Protein and Enhances Rather than Inhibits Complement Activation.
Csincsi ÁI; Szabó Z; Bánlaki Z; Uzonyi B; Cserhalmi M; Kárpáti É; Tortajada A; Caesar JJE; Prohászka Z; Jokiranta TS; Lea SM; Rodríguez de Córdoba S; Józsi M
J Immunol; 2017 Jul; 199(1):292-303. PubMed ID: 28533443
[TBL] [Abstract][Full Text] [Related]
7. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome.
Józsi M; Strobel S; Dahse HM; Liu WS; Hoyer PF; Oppermann M; Skerka C; Zipfel PF
Blood; 2007 Sep; 110(5):1516-8. PubMed ID: 17495132
[TBL] [Abstract][Full Text] [Related]
8. Disturbed sialic acid recognition on endothelial cells and platelets in complement attack causes atypical hemolytic uremic syndrome.
Hyvärinen S; Meri S; Jokiranta TS
Blood; 2016 Jun; 127(22):2701-10. PubMed ID: 27006390
[TBL] [Abstract][Full Text] [Related]
9. Mutations in Complement Factor H Impair Alternative Pathway Regulation on Mouse Glomerular Endothelial Cells in Vitro.
Loeven MA; Rops AL; Lehtinen MJ; van Kuppevelt TH; Daha MR; Smith RJ; Bakker M; Berden JH; Rabelink TJ; Jokiranta TS; van der Vlag J
J Biol Chem; 2016 Mar; 291(10):4974-81. PubMed ID: 26728463
[TBL] [Abstract][Full Text] [Related]
10. Factor H-related protein 5 interacts with pentraxin 3 and the extracellular matrix and modulates complement activation.
Csincsi ÁI; Kopp A; Zöldi M; Bánlaki Z; Uzonyi B; Hebecker M; Caesar JJ; Pickering MC; Daigo K; Hamakubo T; Lea SM; Goicoechea de Jorge E; Józsi M
J Immunol; 2015 May; 194(10):4963-73. PubMed ID: 25855355
[TBL] [Abstract][Full Text] [Related]
11. Unraveling the Effect of a Potentiating Anti-Factor H Antibody on Atypical Hemolytic Uremic Syndrome-Associated Factor H Variants.
Dekkers G; Brouwer MC; Jeremiasse J; Kamp A; Biggs RM; van Mierlo G; Lauder S; Katti S; Kuijpers TW; Rispens T; Jongerius I
J Immunol; 2020 Oct; 205(7):1778-1786. PubMed ID: 32848031
[TBL] [Abstract][Full Text] [Related]
12. An interactive web database of factor H-associated hemolytic uremic syndrome mutations: insights into the structural consequences of disease-associated mutations.
Saunders RE; Goodship TH; Zipfel PF; Perkins SJ
Hum Mutat; 2006 Jan; 27(1):21-30. PubMed ID: 16281287
[TBL] [Abstract][Full Text] [Related]
13. The effect of electrostatics on factor H function and related pathologies.
Kieslich CA; Vazquez H; Goodman GN; López de Victoria A; Morikis D
J Mol Graph Model; 2011 Aug; 29(8):1047-55. PubMed ID: 21605993
[TBL] [Abstract][Full Text] [Related]
14. An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy.
Yang Y; Denton H; Davies OR; Smith-Jackson K; Kerr H; Herbert AP; Barlow PN; Pickering MC; Marchbank KJ
J Am Soc Nephrol; 2018 Jun; 29(6):1649-1661. PubMed ID: 29588430
[No Abstract] [Full Text] [Related]
15. Factor H and atypical hemolytic uremic syndrome: mutations in the C-terminus cause structural changes and defective recognition functions.
Józsi M; Heinen S; Hartmann A; Ostrowicz CW; Hälbich S; Richter H; Kunert A; Licht C; Saunders RE; Perkins SJ; Zipfel PF; Skerka C
J Am Soc Nephrol; 2006 Jan; 17(1):170-7. PubMed ID: 16338962
[TBL] [Abstract][Full Text] [Related]
16. Deregulation of Factor H by Factor H-Related Protein 1 Depends on Sialylation of Host Surfaces.
Dopler A; Stibitzky S; Hevey R; Mannes M; Guariento M; Höchsmann B; Schrezenmeier H; Ricklin D; Schmidt CQ
Front Immunol; 2021; 12():615748. PubMed ID: 33732239
[TBL] [Abstract][Full Text] [Related]
17. Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities.
Pechtl IC; Kavanagh D; McIntosh N; Harris CL; Barlow PN
J Biol Chem; 2011 Apr; 286(13):11082-90. PubMed ID: 21270465
[TBL] [Abstract][Full Text] [Related]
18. Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome.
Blanc C; Roumenina LT; Ashraf Y; Hyvärinen S; Sethi SK; Ranchin B; Niaudet P; Loirat C; Gulati A; Bagga A; Fridman WH; Sautès-Fridman C; Jokiranta TS; Frémeaux-Bacchi V; Dragon-Durey MA
J Immunol; 2012 Oct; 189(7):3528-37. PubMed ID: 22922817
[TBL] [Abstract][Full Text] [Related]
19. Comparative Analysis of Novel Complement-Targeted Inhibitors, MiniFH, and the Natural Regulators Factor H and Factor H-like Protein 1 Reveal Functional Determinants of Complement Regulation.
Harder MJ; Anliker M; Höchsmann B; Simmet T; Huber-Lang M; Schrezenmeier H; Ricklin D; Lambris JD; Barlow PN; Schmidt CQ
J Immunol; 2016 Jan; 196(2):866-76. PubMed ID: 26643478
[TBL] [Abstract][Full Text] [Related]
20. Rational engineering of a minimized immune inhibitor with unique triple-targeting properties.
Schmidt CQ; Bai H; Lin Z; Risitano AM; Barlow PN; Ricklin D; Lambris JD
J Immunol; 2013 Jun; 190(11):5712-21. PubMed ID: 23616575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
